Seeking Alpha

wired4acure

wired4acure
Send Message
View as an RSS Feed
View wired4acure's Comments BY TICKER:
Latest  |  Highest rated
  • Dendreon Provides A Major Warning To Shareholders [View article]
    thanks Bill for being there and stating the facts- disruptive technology of any kind but especially Biotech does not always prevail based on actual value and what it can do vs. who rice bowl it might break
    Aug 12 11:55 AM | Likes Like |Link to Comment
  • Dendreon Provides A Major Warning To Shareholders [View article]
    I am curious about the motivations of management and major shareholders who have influence. Why the emphasis on debt- the facts are all filed in the Sec reports- the worry has been there for all to see. Without a conference call there has been no discussion of the other news, margins, cost controls or future earning trend- only and emphasis on the note due 2016. If there is a real effort to sell the company or take a partner is this anyway to go about it? Or is the whole effort to shake out the retail investors and reduce the short interest. I would think the shorts will now hang in and work to drive out the last penny.
    Aug 12 10:48 AM | Likes Like |Link to Comment
  • Dendreon Provides A Major Warning To Shareholders [View article]
    Shouldn't the patents be worth something in addition to the revenue hard assets?
    Aug 12 10:03 AM | Likes Like |Link to Comment
  • New Provenge Data: Reasons For Optimism On DNDN [View article]
    good article - seems to have flushed out some bears and hit a nerve. Time will tell
    Jul 8 09:05 AM | 1 Like Like |Link to Comment
  • Dendreon: An Update On The Debt Situation [View article]
    google- Treatment with PROVENGE® (sipuleucel-T) Induces Antigen Spread Associated with Overall Survival Benefits In Advanced Prostate Cancer

    May 20 2014

    “These data further elucidate the mechanism of PROVENGE in the treatment of mCRPC and the important role immunotherapy plays in the prescribing practices of urologists and oncologists, which may improve outcomes for patients,” said Andrew S. Sandler, M.D., executive vice president and chief medical officer at Dendreon. “The elevated immune response against prostate-specific antigen (PSA) in the ProACT and IMPACT studies is correlated with overall survival, and may point to a useful biomarker of treatment benefit.”


    IMHO good reason to believe there is light at the end and that it is not a train- bio marker, or approval for early use will ignite this stock and burn the shorts
    Jun 18 11:30 AM | 3 Likes Like |Link to Comment
  • Dendreon Pushes Closer To The Brink [View article]
    My guess as to why management is not discussing the debt as they are gun shy about making any promises until a deal is inked. Given the litigation they have already experienced how can they? What I do not understand is why were are not hearing more about actual results. Falling share price does no help anyone who has an interest in this technology succeeding.

    What about the efficacy of this treatment? Are we ever going to hear how the men are doing that are being treated over the past two years. Isn't that the point? I would like to hear something from the medical community- is Provenge going to be extended to patients in early stages of cancer? If so when. The answer to these questions will tell more about the future than anything I am seeing discussed post the earning announcement.
    May 12 08:44 AM | 3 Likes Like |Link to Comment
  • Dendreon: Is It Going To Get Out Of This Mess? [View article]
    Who say they are going to lose money in Europe. Their R&D knowledge must be worth something. The I have is- Can BP and possible suiters replace this effort and learn the processing if they want to duplicate it once the patents runout cheaper than they can acquire Dendreon. My guess is no. Somehow I thought that a treatment without the severe side effects for a major cancer like Pro was pretty exciting…Estimated new cases and deaths from prostate cancer in the United States in 2014:New cases: 233,000Deaths: 29,480- especially when it is allowed to be used in earlier stages.
    May 11 12:11 PM | 6 Likes Like |Link to Comment
  • Dendreon: How About Some Good News For Once? [View article]
    Short interest may have declined from high but it is still significant if any good news or change of course for the positive is revealed.

    4/15/2014 40,754,065 av vol 2,460,241 days to cover 16.565070
    May 3 10:36 AM | Likes Like |Link to Comment
  • Dendreon: How About Some Good News For Once? [View article]
    Any thoughts on what Johnson is giving up in terms of the bonus he would have received for selling the company?
    Apr 29 09:45 AM | Likes Like |Link to Comment
  • Another Day, Another Major Shale Discovery [View article]
    considering how much money we pay the in FEDERAL taxes- we should be able to demand a national energy strategy- all these studies and whining about fossil fuels vs alternative energy is just noise- Like the mess the FEDS have made of health care we spend spend spend and get dribble from Washington DC and the various FEDERAL agencies that should be held accountable. Boon Pickens tried to goad them into a real policy and yet here we sit 5+ years and Obama and his handmaidens and stooges have yet to articulate a real way ahead to secure our national survival with an intelligent plan to address energy consumption, export, and reserve management. SHAME on them all. NOT one more tax dollar dime for alternative energy until they address the whole of our engery needs and resources.
    Mar 3 10:37 AM | 6 Likes Like |Link to Comment
  • Cytori Therapeutics: Global Patient Stem Cell Demand Builds, Important Short-Term Catalysts Ahead [View article]
    The stakes are high- commercial interests in other solutions have huge influence on FDA-

    The end the mess the health industry in the US finds itself in will be what turns the tide - given that we spend more than another modern society on medicine and do not have survival statistics that back up that investment means something has to give. Cytori offers the potential for many cost effective treatments for many different medical conditions- ignoring the potential will only cause the world medical community to offer opportunities for more offshore clinics- it is clearly already happening. Once results are publicized and success is in the mainstream media a major FDA capitulation will be forced- especially if more and more folks are forced to pay huge deductibles- One might as well go overseas for cheaper more effective course of therapies than be forced to submit to the insurance industry choices and FDA 's "safe" 20th Century treatments
    Feb 13 03:26 PM | 1 Like Like |Link to Comment
  • Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2014 Genitourinary Cancer Symposium (ASCO GU) [View article]
    Appears as though there are going to be many more patients for whom Provenge is an appropriate treatment- with limited side effects
    Feb 5 09:20 AM | Likes Like |Link to Comment
  • Dendreon Is A Steal Compared To New Drug Development [View article]
    thanks for the well articulated argument in favor of holding this for the eventual turn-around. Odds seem to be in favor of longs, but that has been the carrot a long time. Now we need to see some follow-thru and execution from Dendreon management.
    Dec 18 02:19 PM | 4 Likes Like |Link to Comment
  • Cytori Therapeutics $531,000,000 Agreement - Money Talks [View article]
    Well done Wall Street Titan , my only comment is good for us that this market in Asia and Australia because of the added advantage of being beyond the Obamacara battle. Lets see the technology proven in these emerging economies. See if this does not force FDA to catch-up and be pressured by US medical interests losing business to Medical Tourism. Medical solutions at a discount with a vacation as a bonus have a big allure to Europeans - can the US patient be far behind?
    Nov 6 01:04 PM | 5 Likes Like |Link to Comment
  • Wedbush says Dendreon deal makes little sense for Big Pharma [View news story]
    no vision + no imagination = analyst with short position
    Oct 28 01:12 PM | Likes Like |Link to Comment
COMMENTS STATS
40 Comments
62 Likes